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Summary
Background Buruli ulcer, caused by Mycobacterium ulcerans, was identiﬁ ed as a neglected emerging infectious disease 
by WHO in 1998. Although Buruli ulcer is the third most common mycobacterial disease worldwide, understanding 
of the disease is incomplete. We analysed a large cohort of laboratory-conﬁ rmed cases of Buruli ulcer from Pobè, 
Benin, to provide a comprehensive description of the clinical presentation of the disease, its variation with age and 
sex, and its eﬀ ect on the occurrence of permanent functional sequelae.
Methods Between Jan 1, 2005, and Dec 31, 2011, we prospectively collected clinical and laboratory data from all 
patients with Buruli ulcer diagnosed at the Centre de Dépistage et de Traitement de l’Ulcère de Buruli in Pobè, Benin. 
We followed up patients to assess the frequency of permanent functional sequelae. All analyses were done on cases 
that were laboratory conﬁ rmed.
Findings 1227 cases of laboratory-conﬁ rmed Buruli ulcer were included in the analysis. Typically, patients with Buruli 
ulcer were children (median age at diagnosis 12 years) presenting with a unique (1172 [96%]) large (≥15 cm, 444 [36%]) 
ulcerative (805 [66%]) lesion of the lower limb (733 [60%]). Atypical clinical presentation of Buruli ulcer included 
Buruli ulcer osteomyelitis with no identiﬁ able present or past Buruli ulcer skin lesions, which was recorded in at least 
14 patients. The sex ratio of Buruli ulcer widely varied with age, with male patients accounting for 57% (n=427) of 
patients aged 15 years and younger, but only 33% (n=158) of those older than 15 years (odds ratio [OR] 2·59, 
95% CI 2·04–3·30). Clinical presentation of Buruli ulcer was signiﬁ cantly dependent on age and sex. 54 (9%) male 
patients had Buruli ulcer osteomyelitis, whereas only 28 (4%) of female patients did (OR 2·21, 95% CI 1·39–3·59). 
1 year after treatment, 229 (22% of 1043 with follow-up information) patients presented with permanent functional 
sequelae. Presentation with oedema, osteomyelitis, or large (≥15 cm in diameter), or multifocal lesions was 
signiﬁ cantly associated with occurrence of permanent functional sequelae (OR 7·64, 95% CI 5·29–11·31) and 
operationally deﬁ nes severe Buruli ulcer.
Interpretation Our ﬁ ndings have important clinical implications for daily practice, including enhanced surveillance 
for early detection of osteomyelitis in boys; systematic search for M ulcerans in osteomyelitis cases of non-speciﬁ c 
aspect in areas endemic for Buruli ulcer; and speciﬁ c disability prevention for patients presenting with osteomyelitis, 
oedema, or multifocal or large lesions. Our ﬁ ndings also suggest a crucial underestimation of the burden of Buruli 
ulcer in Africa and raise key questions about the contribution of environmental and physiopathological factors to the 
recorded heterogeneity of the clinical presentation of Buruli ulcer.
Funding Agence Nationale de la Recherche (ANR), Fondation Raoul Follereau, Fondation pour la Recherche Médicale 
(FRM), and Institut des Maladies Génétiques (IMAGINE).
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Introduction
Buruli ulcer, caused by Mycobacterium ulcerans, is the 
third most common mycobacteriosis worldwide, after 
tuberculosis and leprosy.1 It mostly aﬀ ects rural areas of 
tropical countries. Although no oﬃ  cial estimate of global 
incidence is available at present, west Africa is the main 
endemic zone, with more than 4000 new cases reported 
by Côte d’Ivoire, Ghana, and Benin in 2010.2 Buruli ulcer 
is a devastating necrotising skin infection classically 
characterised by preulcerative lesions (nodules, plaques, 
oedematous inﬁ ltration), which develop into deep ulcers 
with undermined edges that can spread to an entire limb 
and disseminate to the bone. Osteomyelitis occurs in 
5–10% of patients with Buruli ulcer and is usually 
concomitant to a skin lesion.3 In some patients, most of 
whom are children, Buruli ulcer causes lifelong 
functional sequelae.
This disease was ﬁ rst reported in the late 19th century, 
but became a public health problem in the 1980s. WHO 
formally identiﬁ ed Buruli ulcer as a neglected emerging 
tropical disease with the launch of its global initiative 
against Buruli ulcer in 1998.4 The increase in the number 
of cases was too large to be attributed exclusively to a 
previous lack of awareness and has been explained in 
several instances by local environmental events, such as 
changes in forest cover, ﬂ ooding, the building of dams, 
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or irrigation.5 Several risk factors for Buruli ulcer have 
been repeatedly identiﬁ ed and include proximity to 
stagnant or slow-ﬂ owing bodies of water, poor wound 
care, and not wearing protective clothing (eg, long-
sleeved shirts or shoes).6–9 The exact mode of 
transmission is unclear, and might involve direct 
transmission of the bacterium from the environment to 
wounded skin or indirect transmission mediated by a 
biting vector insect.10–12
The ﬁ rst comprehensive epidemiological description of 
Buruli ulcer dates from 1971, with the seminal report on 
the prospective follow-up of epidemics in the Kinyara 
settlement, in which about 10% of 2500 initially unaﬀ ected 
refugees developed the disease after moving into this zone 
of endemic Buruli ulcer in Uganda.13 This study remains 
unique in its almost experimental setting and it led to the 
ﬁ rst analysis of the incubation period for Buruli ulcer, the 
age-speciﬁ c and sex-speciﬁ c incidence of Buruli ulcer, and 
the eﬀ ect of the distance between the patients’ dwelling 
and the water source on risk of Buruli ulcer. The 1999 
Ghana national case search14 included the largest number 
of patients (>5000) studied worldwide so far and provided 
information about the age and sex of patients and the site 
of lesions. The Beninese Zagnanado study assessed 
1630–2399 cases, but did not clearly specify the proportion 
of these cases conﬁ rmed by laboratory tests.3,15,16 A short 
report described the distribution of age, sex, site, and type 
of lesions for 2598 patients attending four centres in 
Benin, including Pobè, in 2003–05.17 Finally, a series of 
750 cases focused on the site of Buruli ulcer lesions.18 
Other studies have provided valuable descriptions of 
smaller case series (100–300 patients; appendix).
Although of great interest, each of these studies had 
substantial limitations, such as the use of a purely 
descriptive approach (ie, no measurement of association), 
a large proportion of diagnoses being retrospective and 
scar-based or prospective but only clinical, or the inclusion 
of a large proportion of individuals for whom key data 
were missing. WHO insists on laboratory conﬁ rmation of 
clinically suspected Buruli ulcer, with possible diﬀ erential 
diagnoses including other tropical ulcers, skin fungal 
infections, or cutaneous tuberculosis.1 The most sensitive 
and speciﬁ c test is the detection of M ulcerans DNA by 
PCR on ﬁ ne-needle aspiration, or biopsy or swab 
samples.1,19 Direct smear examination after Ziehl-Neelsen 
staining, culture, or histopathology can also be used. In 
the four largest epidemiological studies of Buruli ulcer (ie, 
≥750 individuals), laboratory conﬁ rmation of diagnosis 
was available for about 50% of cases at best.13–15,18 In this 
study, we analyse a large cohort of laboratory-conﬁ rmed 
cases of Buruli ulcer from Pobè, Benin, to provide a robust 
and comprehensive description of the clinical presentation 
of Buruli ulcer, of its variation with age and sex, and its 
eﬀ ect on the frequency of permanent functional sequelae 
as assessed after systematic follow-up.
Methods
Participants and study design  
Between Jan 1, 2005, and Dec 31, 2011, we prospectively 
collected clinical and laboratory data from all consecutive 
patients treated for Buruli ulcer at the Centre de 
Dépistage et de Traitement de l’Ulcère de Buruli 
(CDTUB) in Pobè, Benin. We prospectively recorded age 
at diagnosis, sex, geographic origin of the patient, clinical 
form (nodule, plaque, oedema, ulcer, osteomyelitis), 
WHO lesion size category (maximum diameter <5 cm, 
5–15 cm, ≥15 cm), and site (right or left, upper or lower 
limb, thorax, abdomen, head, perineum), laboratory 
conﬁ rmation test (culture, Ziehl-Neelsen staining or 
highly speciﬁ c IS2404 PCR), HIV status, medical or 
surgical treatment, and time to healing. Notably, a patient 
with Buruli ulcer might have lesions at one or more sites 
(deﬁ ning multifocality—eg, right and left arms), but also 
several forms at one site (eg, an ulcerated plaque).
We followed up the patients of our cohort to assess the 
frequency of permanent functional sequelae, ranging 
from the loss of ten or more degrees of joint mobility to 
the amputation of a whole limb. Access to the registry 
Ulcer Plaque Oedema Nodule Osteo-
myelitis
0
20
40
60
80
Lower
limb
Upper
limb
Trunk Other
Un
ifo
cal
Mu
ltif
oc
al <5 cm 5–15 cm ≥15 cm
100
Pr
op
or
tio
n 
 o
f p
at
ie
nt
s (
%
)
Clinical form Site Multifocality Size
Figure 1: Clinical presentation of Buruli ulcer (Pobè, Benin, laboratory-conﬁ rmed cases, 2005–11)
Note that a patient with Buruli ulcer might have lesions at one or more sites (deﬁ ning multifocality—eg, right and left arms), but also several forms at a single site 
(eg, an ulcerated plaque).
See Online for appendix
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was approved by the institutional review board of the 
CDTUB and the national Buruli ulcer control authorities. 
In accordance with WHO recommendations for 
diagnosis of Buruli ulcer (ie, conﬁ rmation of diagnosis by 
at least one laboratory test; appendix), we focused our 
descriptive and analytical studies on laboratory-conﬁ rmed 
cases only. We described the clinical presentation of Buruli 
ulcer and analysed the eﬀ ect of age at diagnosis and sex on 
this presentation. Ten elements of clinical presentation and 
outcome were assessed: male sex; localisation of a lesion on 
the upper body; presence of a nodule, plaque, ulcer, 
oedema, or osteomyelitis; largest lesion with a maximum 
diameter exceeding 15 cm; presence of multifocal lesions; 
and the frequency of permanent functional sequelae. The 
upper body was deﬁ ned as the head, thorax, abdomen, and 
arms, and the lower body as the perineum and legs.
Statistical analysis  
We systematically ﬁ tted three logistic regression models, 
one with age, one with sex, and a third with both age and 
sex as explanatory variables for each of the ten elements 
of Buruli ulcer clinical presentation and outcome. We 
then screened each element of clinical presentation of 
Buruli ulcer for their eﬀ ect on the frequency of permanent 
functional sequelae in both univariable and multivariable 
models. We operationally deﬁ ned severe Buruli ulcer as 
presenting with at least one clinical element at higher risk 
for permanent functional sequelae. We further validated 
our deﬁ nition by assessing the eﬀ ect of Buruli ulcer 
severity on time to healing (Wilcoxon test). Age was 
analysed as a continuous variable and modelled by means 
of multiple fractional polynomials (with corresponding p 
values referred to as MFP-p).20 For ease of interpretation, 
odds ratios (OR) for dichotomised age with a cutoﬀ  point 
at 15 years were also reported (with corresponding OR 
referred to as OR15). Parameter estimation and signiﬁ cance 
testing were done within the classical maximum 
likelihood framework. The analyses were done with R 
statistical analysis software (version 3.1.0, glm functions), 
together with the additional mfp (version 1.4.9) and ggplot2 
(version 0.9.3.1) packages.21–23
Role of the funding source  
The funders of the study had no role in study design; 
data collection, data analysis, data interpretation; writing 
of the report or in the decision to submit the paper for 
publication. AAl had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
1511 patients with Buruli ulcer were treated between Jan 1, 
2005, and Dec 31, 2011, at the CDTUB, Pobè, Benin. The 
appendix shows the distribution of cases according to year 
of diagnosis, month of diagnosis, and management 
characteristics (antibiotic therapy, surgery, hospital 
admission, and time to healing). 1251 (83%) cases were 
conﬁ rmed by one or more laboratory tests. PCR results 
were positive in 1177 (78%) cases, Ziehl-Neelsen staining 
was positive in 842 (56%) cases, and culture was positive 
in 214 (14%) cases (appendix). To ensure maximum 
robustness and homogeneity in our dataset, we focused 
Figure 2: Clinical presentation of Buruli ulcer as a function of age (Pobè, Benin, laboratory-conﬁ rmed cases, 
2005–11)
Red circles show the percentage of individuals with the clinical characteristic by age groups with a width of 5 years. 
The area of circles are scaled to the total number of individuals in the age group (ranging from about 20 to 350). 
The blue lines show the prediction of the logistic regression model, as ﬁ tted by the fractional polynomial method. 
Total counts of individuals in each regression model were 1163 for size and 1224 for all other analyses.
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our analyses on 1227 laboratory-conﬁ rmed cases without 
HIV co-infection. We describe Buruli ulcer clinical 
presentation, analyse the eﬀ ect of age and sex on Buruli 
ulcer clinical presentation, and assess the relation between 
clinical presentation and the occurrence of permanent 
functional sequelae, incidentally leading to the proposal of 
an operational deﬁ nition of severe Buruli ulcer.
Patients with typical Buruli ulcer were children 
presenting with one large ulcerative lesion of the lower 
limb, as detailed below (ﬁ gure 1). The median age at 
diagnosis was 12 years (IQR 7–28 years; mean 19·3 years). 
Comparison with the median age of the Beninese 
population (18 years in 201024) shows that Buruli ulcer is 
over-represented in children. 1172 (96%) patients 
presented with one localisation and 444 (36%) patients 
presented with a lesion of more than 15 cm in diameter 
(ﬁ gure 1).  733 (60%) patients presented with a lesion on 
the lower limb. 805 (66%) patients had ulcers, 668 (54%) 
had plaques, 307 (25%) had oedema, and 42 (3%) had 
nodules. 82 (7%) patients had osteomyelitis (ﬁ gure 1), of 
whom at least 14 (17%) presented with no identiﬁ able 
present or past Buruli ulcer skin lesions (notably, several 
of these patients had ﬁ stulisation of the bone infection to 
the skin, as commonly recorded in osteomyelitis).
Although the overall sex ratio of the patients was 
balanced (640 [52%] women vs 587 [48%] men, p=0·13), a 
major distortion of the sex ratio was recorded as a function 
of age, with males being predominant in younger patients 
and females in older patients (OR15 2·59, 95% CI 
2·04–3.30, MFP-p<0·0001, ﬁ gure 2A). Speciﬁ cally, male 
patients accounted for 427 (57%) of the patients younger 
than 15 years, but only 158 (33%) of those older than 
15 years (table 1). This eﬀ ect cannot be accounted for by 
the demography of the country because the Beninese 
population shows a balanced sex ratio both in patients 
younger than 15 years and in those older than 15 years.24 
Thus, age at diagnosis was substantially diﬀ erent between 
the male and female patients with Buruli ulcer: the 
median age at diagnosis was 10 years (mean 16 years) for 
male patients and 15 years (22·5 years) for female patients 
(p<0·0001).
Table 1 and ﬁ gure 2 show the complete set of results 
regarding clinical presentation as a function of age and 
sex. 54 (9%) men had osteomyelitis, but only 28 (4%) 
women did (OR 2·21, 95% CI 1·39–3·59; p=0·0007; 
table 1). Age was signiﬁ cantly associated with the frequency 
of clinical forms such as developing lesions on the upper 
body, presenting with a plaque, and presenting with an 
ulcer (table 1). Younger patients were prone to developing 
lesions on the upper body (OR15 2·00, 95% CI 1·58–2·55, 
MFP-p<0·0001; ﬁ gure 2) and to present with a plaque 
(1·90, 1·51–2·40; MFP-p<0·0001; ﬁ gure 2D). Conversely, 
older patients were more likely to present with ulcers (OR15 
0·68, 95% CI 0·53–0·88; MFP-p=0·0004; ﬁ gure 2E). 
Additionally, we noted a number of borderline signiﬁ cant 
associations; nodules were more frequent in female 
patients (OR 0·53, 95% CI 0·27–1·01, p=0·05; table 1) than 
in male patients, and osteomyelitis was more frequent in 
younger patients than in older patients (OR15 1·46, 
0·91–2·41, MFP-p=0·06; ﬁ gure 2G).
Follow-up information was available for a median of 
359 days for 1043 (85%) patients, 229 (22%) of whom 
Patients, n (%) Univariable* Bivariable†
 Crude OR 
(95% CI)
p value‡ Adjusted OR 
(95% CI)
p value
Male sex
Age
Continuous ·· ·· <0·0001 ··  ··
>15 years 158 (34%) 1 ·· ··  ··
≤15 years 427 (57%) 2·59 (2·04–3·30) <0·0001 ·· ··
Upper body lesion
Age
Continuous ·· ·· <0·0001 ·· <0·0001
>15 years 150 (32%) 1 ·· 1 ··
≤15 years 364 (48%) 2·00 (1·58–2·55) <0·0001 2·13 (1·67–2·74) <0·0001
Sex
Female 275 (43%) 1 ·· 1 ··
Male 239 (41%) 0·91 (0·73–1·14) 0·4241  0·78 (0·61–0·98) 0·0366
Nodule
Age
Continuous ·· ·· 0·7496 ·· 0·4886
>15 years 19 (4%) 1 ·· 1 ··
≤15 years 23 (3%) 0·75 (0·40–1·41) 0·3639 0·85 (0·45–1·62) 0·6247
Sex
Female 28 (4%) 1 ·· 1 ··
Male 14 (2%) 0·53 (0·27–1·01) 0·0528 0·51 (0·26–0·99) 0·0427
Plaque
Age
Continuous ·· ·· <0·0001 ·· <0·0001
>15 years 211 (45%) 1 ·· 1 ··
≤15 years 457 (61%) 1·90 (1·51–2·40) <0·0001 2·06 (1·62–2·63) <0·0001
Sex
Female 361 (56%) 1 ·· 1 ··
Male 307 (52%) 0·85 (0·68–1·06) 0·1491 0·75 (0·60–0·95) 0·0167
Ulcer
Age
Continuous ·· ·· 0·0004 ·· <0·0001
>15 years 333 (71%) 1 ·· 1 ··
≤15 years 469 (62%) 0·68 (0·53–0·88) 0·0024 0·64 (0·49–0·82) 0·0004
Sex
Female 405 (63%) 1 ·· 1 ··
Male 400 (68%) 1·24 (0·98–1·57) 0·0731 1·36 (1·07–1·74) 0·0120
Oedema
Age
Continuous ·· ·· 0·0445 ··  0·0413
>15 years 103 (22%) 1 ·· 1 ··
≤15 years 204 (27%) 1·33 (1·01–1·75) 0·0390 1·35 (1·02–1·78) 0·0349
Sex
Female 160 (25%) 1 ·· 1 ··
Male 147 (25%) 1·00 (0·77–1·30) 0·9863 0·95 (0·73–1·24) 0·7214
(Table 1 continues on next page)
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presented with permanent functional sequelae, including 
ten amputations (<1%; ﬁ ve on the upper limb, ﬁ ve on the 
lower limb, ranging from one ﬁ nger to a whole limb). 
Age and sex were not signiﬁ cantly associated with the 
frequency of permanent functional sequelae (table 1), 
whereas patients presenting with oedema, bone lesions, 
large lesions (more than 15 cm of diameter), or multifocal 
lesions were at signiﬁ cantly increased risk of permanent 
functional sequelae (table 2). On the basis of this ﬁ nding, 
we propose an operational deﬁ nition of a severe case of 
Buruli ulcer as a patient presenting with at least one of 
these clinical characteristics. 616 (50%) patients had 
severe Buruli ulcer. 192 (37%) patients with severe Buruli 
ulcer developed permanent functional sequelae compared 
with 37 (7%) patients with non-severe Buruli ulcer 
(OR 7·64, 95% CI 5·29–11·31, p<0·0001; ﬁ gure 3). A 
multivariable regression analysis showed some 
dependencies between the four clinical components of 
severity: only osteomyelitis and lesion size had 
independent signiﬁ cant eﬀ ects on sequelae (osteomyelitis, 
OR 6·48, 95% CI 2·27–20·9, p=0·0004; lesion size, 
6·95, 4·70–10·4, p<0·0001). In further validation of the 
relevance of our deﬁ nition of severity, the median time to 
healing increased from 81 days in patients with non-
severe Buruli ulcer to 107 days in patients with severe 
Buruli ulcer (p<0·0001).
Discussion
Despite its discovery more than a century ago and its 
rapid progression since the 1980s, Buruli ulcer remains 
one of the most neglected infectious diseases. With our 
unique collection of data recorded prospectively during 
7 years at a leading treatment centre for Buruli ulcer 
(appendix), we have generated a comprehensive 
epidemiological description of Buruli ulcer in a west 
African setting, including systematic follow-up for 
permanent functional sequelae. This work provides 
insight into the clinical presentation and outcome of 
Buruli ulcer and proposes guidelines for future research 
eﬀ orts (panel). By contrast with other studies, this study 
was based on a large number of prospectively diagnosed 
laboratory-conﬁ rmed cases (95% of which by PCR) with 
a very low proportion of missing data throughout the 
analyses. Several characteristics of the disease 
consistently reported in previous studies were conﬁ rmed 
(appendix), a strong support to the generalisability of our 
ﬁ ndings: Buruli ulcer being mainly a paediatric disease 
(median age of 12 years at diagnosis); the preponderance 
of unifocal lesions (>90%); the predominance of lesions 
on the lower limbs (about 60%); ulcer as the most 
frequent clinical presentation (about 70%); a not 
unsubstantial proportion of patients presenting with 
osteomyelitis (>5%); and a high frequency of permanent 
functional sequelae (>20%). Of the many additional 
ﬁ ndings reported in this study, ﬁ ve are of particular 
importance and further discussed below: the variation of 
Buruli ulcer sex ratio with age; the over-representation of 
boys among patients with Buruli ulcer osteomyelitis; the 
existence of Buruli ulcer osteomyelitis patients with no 
identiﬁ able present or past Buruli ulcer skin lesions; the 
strong association between clinical presentation and the 
Patients, n (%) Univariable* Bivariable†
 Crude OR 
(95% CI)
p value‡ Adjusted OR 
(95% CI)
p value
(Continued from previous page)
Osteomyelitis
Age
Continuous ·· ·· 0·0560 ·· 0·1993
>15 years 25 (5%) 1 ·· 1 ··
≤15 years 57 (8%) 1·46 (0·91–2·41) 0·1181 1·23 (0·76–2·05) 0·4106
Sex
Female 28 (4%) 1 ·· 1 ··
Male 54 (9%) 2·21 (1·39–3·59) 0·0007 2·09 (1·30–3·38) 0·0019
Lesion size ≥15 cm
Age
Continuous ·· ·· <0·0001 ·· <0·0001
>15 years 189 (42%) 1 ·· 1 ··
≤15 years 255 (36%) 0·78 (0·61–0·99) 0·0422 0·74 (0·57–0·94) 0·0157
Sex
Female 226 (36%) 1 ·· 1 ··
Male 218 (40%) 1·18 (0·93–1·49) 0·1746 1·28 (1·00–1·63) 0·0466
Multifocal lesions
Age
Continuous ·· ·· 0·1292 ·· 0·1308
>15 years 18 (4%) 1 ·· 1 ··
≤15 years 35 (5%) 1·23 (0·69–2·24) 0·4878 1·22 (0·68–2·26) 0·5020
Sex
Female 27 (4%) 1 ·· 1 ··
Male 26 (4%) 1·05 (0·60–1·82) 0·8654 0·97 (0·55–1·70) 0·9114
Severe form
Age
Continuous ·· ·· 0·0003 ·· 0·0002
>15 years 245 (52%) 1 ·· 1 ··
≤15 years 371 (49%) 0·90 (0·71–1·13) 0·3537 0·85 (0·67–1·08) 0·1736
Sex
Female 306 (48%) 1 ··  1 ··
Male 310 (53%) 1·22 (0·97–1·53) 0·0842  1·27 (1·01–1·59) 0·0416
Permanent sequelae
Age
Continuous .. ·· 0·1098 ·· 0·2006
>15 years 79 (20%) 1 ·· 1 ··
≤15 years 150 (23%) 1·20 (0·88–1·63) 0·2479 1·13 (0·83–1·55) 0·4425
Sex
Female 109 (20%) 1 ·· 1 ··
Male 120 (24%) 1·30 (0·97–1·75) 0·0783  1·26 (0·93–1·70) 0·1289
OR=odds ratio· *Univariable analysis of each clinical characteristic as a function of the predictors age and sex. 
†Bivariable analysis of each clinical characteristic as a function of the predictors age and sex. ‡Age was analysed both as 
a continuous variable modelled with multiple fractional polynomials (MFP) and as a categorical variable with a cutoﬀ  
point at 15 years (ﬁ gure 2 shows MFP visualisation and appendix shows MFP formulas).
Table 1: Eﬀ ect of age at diagnosis and sex on clinical presentation and outcome of Buruli ulcer 
(laboratory-conﬁ rmed cases, 2005–11, Pobè, Benin): univariable and bivariable analysis
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development of permanent functional sequelae; and the 
underestimation of the burden of Buruli ulcer in Africa.
Although overall balanced, the sex ratio varied widely 
with age. Male patients accounted for signiﬁ cantly more 
than half of the patients diagnosed younger than 15 years, 
but only a third of those diagnosed older than 15 years. 
Such sex ratio variation with age has been previously 
reported,7,13,14,25,26 but surprisingly has always been 
disregarded or even denied in review papers.1,6,19,27–29 Sexual 
dimorphism is frequently recorded in human infectious 
diseases.31 In the context of human mycobacteriosis, rare 
infections with Mycobacterium marinum or Mycobacterium 
avium intracellulare and common infections with 
Mycobacterium leprae and Mycobacterium tuberculosis are 
more frequent in adult men than they are in adult 
women.31–35 Explanatory hypotheses include diﬀ erential 
exposure, diﬀ erential host response, or both, according to 
sex. Experimental studies comparing the inoculation of 
intact male mice, female mice, and castrated male mice 
have shown that high testosterone concentrations impair 
resistance to M marinum.36 In our observational study in 
natura, infection with M ulcerans followed the opposite 
pattern in adults, showing that despite its close relation to 
M marinum, the toxin-secreting M ulcerans has a distinctive 
physiopathology. This information is of particular interest 
and substantiates the need for speciﬁ c studies that aim to 
understand the mechanisms underlying the age-
dependent dynamics of the sex ratio in Buruli ulcer.
The risk of developing Buruli ulcer osteomyelitis was 
signiﬁ cantly greater in male patients than in female 
patients (OR 2·21, 95% CI 1·39–3·59), and we also 
recorded borderline signiﬁ cant association with younger 
age (ﬁ gure 2G, table 1). No eﬀ ects of age and sex on the 
occurrence of Buruli ulcer osteomyelitis were detected in 
a previous study of BCG eﬃ  cacy in Buruli ulcer.37 In view 
of our results, this diﬀ erence could mean that the 
previous study had insuﬃ  cient power to detect these 
eﬀ ects—the power to detect an OR of 2·2 in a sample of 
186 male patients and 187 female patients, assuming a 
type I error of 0·05, is less than 40%.37 Because of its 
crucial clinical and physiopathological relevance, this 
result needs to be conﬁ rmed in independent well 
powered studies of Buruli ulcer, but such an excess of 
males has also been reported in non-Buruli ulcer 
osteomyelitis.38 Close monitoring of boys with Buruli 
ulcer should be undertaken to detect osteomyelitis as 
early as possible. Understanding why boys are prone to 
Buruli ulcer osteomyelitis (eg, hormonal or host genetics 
components) is of major physiopathological interest and, 
again, should be the focus of future studies.
We report for the ﬁ rst time, to our knowledge, cases of 
Buruli ulcer osteomyelitis with no identiﬁ able present or 
past Buruli ulcer skin lesions and estimated that these 
so-called exclusive Buruli ulcer osteomyelitis cases represent 
n (%) with 
permanent 
sequelae
Univariable* Multivariable†
Crude OR
(95% CI)
p value Adjusted OR 
(95% CI)
p value
Upper body
Unaﬀ ected 124 (21%) 1 ·· 1 ··
Aﬀ ected 105 (24%) 1·22 (0·91–1·63) 0·1930 1·59 (1·10–2·30) 0·0128
Nodule
Absence 227 (23%) 1 ·· 1 ··
Presence 2 (5%) 0·20 (0·03–0·65) 0·0045 0·47 (0·07–1·73) 0·2829
Plaque
Absence 143 (31%) 1 ·· 1 ··
Presence 86 (15%) 0·40 (0·29–0·54) <0·0001 0·64 (0·45–0·92) 0·0156
Ulcer
Absence 69 (20%) 1 ·· 1 ··
Presence 160 (23%) 1·24 (0·91–1·71) 0·1758 2·07 (1·33–3·28) 0·0012
Oedema
Absence 146 (19%) 1 ·· 1 ··
Presence 83 (31%) 1·89 (1·38–2·59) <0·0001 1·39 (0·90–2·15) 0·1347
Osteomyelitis
Absence 185 (19%) 1 ·· 1 ··
Presence 44 (66%) 8·18 (4·87–14·1) <0·0001 6·48 (2·27–20·9) 0·0004
Size
<15 cm 47 (8%) 1 ·· 1 ··
≥15 cm 153 (41%) 8·30 (5·82–12·0) <0·0001 6·95 (4·70–10·4) <0·0001
Multifocal
No 210 (21%) 1 ·· 1 ··
Yes 19 (49%) 3·59 (1·87–6·87) 0·0002 0·91 (0·37–2·18) 0·8328
Severe form
No 37 (7%) 1 ·· ·· ··
Yes 192 (37%) 7·64 (5·29–11·3) <0·0001 ·· ··
OR=odds ratio. *Univariable analysis of permanent functional sequelae as a function of each of the nine predictors. 
†Multivariable analysis of permanent functional sequelae was done as a function of all clinical characteristics (except 
severity).
Table 2: Eﬀ ect of clinical presentation of Buruli ulcer on permanent functional sequelae 
(laboratory-conﬁ rmed cases, 2005–11, Pobè, Benin)
Figure 3: Frequency of permanent functional sequelae in non-severe Buruli 
ulcer versus severe Buruli ulcer (Pobè, Benin, laboratory-conﬁ rmed cases, 
2005–11)
Severe Buruli ulcer was deﬁ ned as presenting with at least one of the following 
clinical elements: oedema, osteomyelitis, multifocal lesions, or large lesions 
(≥15 cm). 
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about 20% of all Buruli ulcer osteomyelitis cases—a lower 
bound estimate in view of the stringent criteria that we 
applied. These patients presented with clinical osteomyelitis 
that was not speciﬁ c to Buruli ulcer in appearance, with 
M ulcerans identiﬁ ed only through systematic laboratory 
investigation. Arguably, recall bias could have resulted in 
previous small skin lesions being overlooked in some of 
these cases, but very likely not in all of them. Even with this 
oversight, this ﬁ nding would remain of fundamental 
clinical, public health, and physiopathological relevance. 
The clinical relevance is obvious: M ulcerans causes 
osteomyelitis in zones endemic with Buruli ulcer, which 
implies that laboratory testing for the bacterium should be 
done and the antibiotic regimen should be adapted. With 
regard to physiopathology, these exclusive cases are a proof 
of concept that osteomyelitis in Buruli ulcer is not 
necessarily the result of an uncontrolled multiplication of 
the bacterium in its elective tissue (skin). At least some 
individuals are susceptible to bone invasion by a small load 
of bacteria without contiguous tissue destruction. 
Importantly, we do not question the route of inoculation of 
M ulcerans in humans—ie, we do not imply that these 
patients were not bitten by a vector insect or did not have a 
bruise that came into contact with contaminated water. 
However, we suggest that some patients with Buruli ulcer 
can develop bone lesions without an overwhelming skin 
reservoir for the mycobacterium. In view of the homogeneity 
of M ulcerans strains at this local scale,39 this suggestion, in 
turn, questions the source of the interindividual variability 
of the human immune response to this infectious agent. 
We deem this is an important point to be urgently 
investigated through ad-hoc studies—eg, human genetic 
studies. This observation also supports the possible 
haematogenous transport of the bacterium from the site of 
inoculation to the bone in some patients with Buruli ulcer.
For the ﬁ rst time, we systematically assessed the 
eﬀ ect of clinical presentation of Buruli ulcer on the 
frequency of permanent functional sequelae. Four 
elements of clinical presentation were associated with a 
longer time to healing and an increased risk of 
permanent functional sequelae. We thus propose an 
operational deﬁ nition of severe Buruli ulcer as a 
clinical course including oedema, osteomyelitis, 
multifocal, or large (≥15 cm) lesions. The estimated 
OR of 7·6 for the development of permanent functional 
sequelae in patients with severe forms of Buruli ulcer 
is compelling and has straightforward clinical 
implications. Patients presenting with any of these four 
types of lesions should beneﬁ t from speciﬁ c clinical 
care, such as enhanced monitoring, intensive 
physiotherapy, and timely reconstruction surgery. Our 
ﬁ nding also raises the question as to why some patients 
with Buruli ulcer develop severe disease. Because the 
delay to diagnosis was unknown in our study and 
previous studies, we can only conjecture that longer 
delay to diagnosis would account for the severity of the 
clinical presentation in a proportion of patients. 
However, we surmise that some patients have severe 
Buruli ulcer despite rapid diagnosis. Identiﬁ cation of 
such patients would be of special interest to investigate 
variations in the host susceptibility to Buruli ulcer.
Several ﬁ ndings in our study suggest the probable 
underestimation of the burden of Buruli ulcer in Africa. 
The incidental observation of patients coming from 
Nigeria to be treated at the Pobè CDTUB (located in 
Benin) shed light on this phenomenon; although the 
annual number of cases declared by Nigeria to the 
WHO is consistently less than ten (eg, seven in 2010),40 
about 20 Nigerian cases have been treated every year in 
Pobè for the past 7 years. Because Nigeria is much larger 
than Benin, the oﬃ  cial ﬁ gures for Nigeria are therefore 
likely to be a severe under estimation. Additionally, so 
far, the failure to diagnose Buruli ulcer with atypical 
clinical presentation, such as exclusive Buruli ulcer 
osteomyelitis, also contributes to the underestimation 
of the burden of Buruli ulcer, because these cases are 
not usually tested for the presence of M ulcerans.
Our results raise several questions that should be 
addressed by speciﬁ c studies in the future, most of 
Panel: Research in context
Systematic review
On March 15, 2010, we searched PubMed with the search terms “buruli OR ulcerans NOT 
corynebacterium” and identiﬁ ed about 600 publications on Buruli ulcer, including many 
isolated case reports. Of papers with epidemiological relevance, roughly 80 were review 
articles, roughly 20 were case-control studies of risk factors of Buruli ulcers, and roughly 
20 were cross-sectional studies or case series of more than ten patients with Buruli ulcer. 
This small number of heterogeneous studies prompted us to undertake a large-scale 
epidemiological study in Benin to present characteristics never found together in 
published epidemiological studies of Buruli ulcer. Our study was representative of Buruli 
ulcer in west Africa, where most cases arise and the number of cases is large; all cases were 
prospectively diagnosed and laboratory-conﬁ rmed; follow-up for permanent functional 
sequelae was systematic; and the clinical course of the disease was carefully recorded 
resulting in sparse missing data. Taking advantage of such a setting, we were able to 
comprehensively describe the clinical presentation of Buruli ulcer to provide a robust and 
powerful analysis of its variation with age and sex and to assess its eﬀ ect on the 
occurrence of permanent functional sequelae, leading to the operational deﬁ nition of 
severe Buruli ulcer.
Interpretation
Our ﬁ ndings are of key public health, clinical, and physiopathological relevance. With respect 
to public health, several of our ﬁ ndings suggest a crucial underestimation of the burden of 
Buruli ulcer in west Africa. We describe a new form of clinical presentation for Buruli ulcer, in 
which patients presented with osteomyelitis with no identiﬁ able present or past Buruli ulcer 
skin lesions. We propose several clinical implications of our study: enhanced surveillance for 
the early detection of osteomyelitis in boys; systematic search for Mycobacterium ulcerans in 
osteomyelitis cases of unspeciﬁ c aspect in areas endemic with Buruli ulcer; and speciﬁ c 
disability prevention for patients presenting with oedema, osteomyelitis, multifocal or large 
lesions (ie, severe Buruli ulcer). Major questions were raised with regard to the environmental 
or biological processes underlying the recorded heterogeneity of clinical presentation of 
Buruli ulcer. Further studies would be of particular interest to decipher the relative 
contributions of the environment, exposure, lifestyle, health-care systems, microbial strains, 
and host genetics to the dynamics and natural history of Buruli ulcer in natural conditions.
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which are in agreement with a recent review.41 Studies of 
the dynamics of the healing of Buruli ulcer should be 
undertaken, with prospective collection of information 
designed to disentangle several situations that we could 
not directly diﬀ erentiate in our study—namely, re-
currence (a short-term infectious clinical relapse 
mediated by live M ulcerans that was incompletely 
eradicated), paradoxical reaction (a non-infectious 
clinical relapse mediated by an immunological event), 
and reinfection (an independent Buruli ulcer infectious 
episode). In several instances, we recorded new Buruli 
ulcer lesions that occurred several years after healing of 
the initial episode (appendix). By analogy with 
tuberculosis, this ﬁ nding suggests reinfection or perhaps 
long-term reactivation of the contained infection. We 
believe that further characterisation of these patients 
would be particularly relevant to better our understanding 
of the human immune response to M ulcerans, especially 
in the prospects of vaccine development (appendix). 
Finally, although we ensured the homogeneity of the 
dataset, the monocentric design of our study restricts the 
number of patients for some important aspects of the 
disease (eg, Buruli ulcer–HIV co-infection), calling for 
further research. The monocentric design of our study 
also raises the important question of the generalisability 
of our ﬁ ndings. We believe our study to be representative 
of Buruli ulcer in tropical zones, where almost all Buruli 
ulcer cases arise. However, large series of conﬁ rmed 
cases from non-tropical zones, such as Australia or 
Japan, will be of particular interest to decipher the 
relative contributions of the environment, exposure, 
lifestyle, health-care systems, microbial strains, and host 
genetics to the development and dynamics of Buruli 
ulcer in humans.
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